Posted by Michael Wonder on 13 Jun 2023
The Supreme Administrative Court did not test Mayzent
12 June 2023 - The Supreme Administrative Court decided on 3 May not to grant a review permit for Mayzent.
This means that the Court of Appeal's ruling stands and that TLV had the right to use Mabthera (rituximab) as comparative treatment/relevant comparison alternative, even though Mabthera is used outside the approved area of use (off-label).
